Results 251 to 260 of about 764,268 (348)

Integrin αvβ6‐Targeted PET/CT Imaging of Non‐Small Cell Lung Cancer with [68Ga]Ga‐Trivehexin: Improved Preoperative Lymph Node Staging and Association with Immunohistochemistry

open access: yesAdvanced Science, EarlyView.
Integrin αvβ6‐targeted [68Ga]Ga‐Trivehexin positron emission tomography/computed tomography (PET/CT) can accurately identify regional lymph nodes and cerebral metastases in non‐small cell lung cancer (NSCLC) compared with 2‐deoxy‐2‐[18F]fluoro‐D‐glucose ([18F]FDG).
Huiqin Wu   +9 more
wiley   +1 more source

An LCN2‐Dependent Positive‐Feedback Loop Between Gastric Cancer Cells and Tumor‐Associated‐Macrophages Mediates Lymphangiogenesis and Lymphatic Metastasis

open access: yesAdvanced Science, EarlyView.
In this study, the expression and function of LCN2 in GC is aimed to investigate and elucidate the mechanisms by which the LCN2‐dependent positive‐feedback loop between GC cells and TAMs drives lymphangiogenesis and lymphatic metastasis. These findings suggest that LCN2 may serve as a potential prognostic biomarker and therapeutic target in GC ...
Zhixin Huang   +15 more
wiley   +1 more source

Comparative Cochlear Transcriptomics in Echolocating Bats and Mouse Reveals Hras as Protector Against Noise‐Induced Hearing Loss

open access: yesAdvanced Science, EarlyView.
Comparative cochlear transcriptomics of noise‐exposed bats (Miniopterus fuliginosus) and mice reveals bat‐specific protection mechanisms for noise‐induced hearing loss (NIHL), identifying Hras as a key hub regulator. Functional studies in mice show hair‐cell‐specific Hras overexpression significantly reduced hair‐cell damage and NIHL by activating the ...
Peng Chen   +9 more
wiley   +1 more source

Metastasis of Carcinoma of the Breast to the Periphery of the Regional Lymph Node Filter

open access: green, 1969
C. D. Haagensen   +9 more
openalex   +2 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy